Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma

Published:2022-07-12 Issue:9 Volume:11 Page:1099-1109
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Forero‐Torres Andres¹,Chandler Jason Claud²,Iyer Swaminathan P.³,Kanate Abraham S.⁴,Quinlan Michelle⁵,Hoever Petra⁶,Izquierdo Miguel⁷,Davis Jaclyn⁵,Madan Sumit⁷

Affiliation:

1. University of Alabama at Birmingham Birmingham Alabama USA

2. West Cancer Center Germantown Tennessee USA

3. Houston Methodist Cancer Center Houston Texas USA

4. West Virginia University Morgantown West Virginia USA

5. Novartis Oncology East Hanover New Jersey USA

6. Novartis Pharma AG Basel Switzerland

7. Cancer Therapy & Research Center San Antonio Texas USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1133

Reference27 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Novel agents in indolent lymphomas

3. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

4. First-line treatment of indolent lymphoma: axing CHOP?

5. Rituximab

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP